About
NASH therapy
Areas of Focus
Categories
Small Molecule PharmaceuticalBiotech
Team (17)
Chief Development Officer
Chief Development Officer
Akero Therapeutics
team_member
Chief Financial Officer & Head of Corporate Development
Chief Financial Officer & Head of Corporate Development
Akero Therapeutics
executive
Chief Operating Officer & Co-Founder
Chief Operating Officer & Co-Founder
Akero Therapeutics
executivefounder
Chief Scientific Officer & Co-Founder
Chief Scientific Officer & Co-Founder
Akero Therapeutics
executivefounder
Chief Technical Officer
Chief Technical Officer
Akero Therapeutics
team_member
Independent Board Member
Akero Therapeutics
team_member
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
6
As Collaborator
0
Total Enrollment
3,920
By Phase
PHASE3: 3PHASE2: 3
By Status
RECRUITING: 2ACTIVE_NOT_RECRUITING: 2COMPLETED: 2
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
Today
Hover over trial bars to see details
Recent Trials
NCT06528314Lead Sponsor
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
PHASE3Recruiting
1,150 participants
Started: Sep 4, 2024 · Completed: Oct 31, 2029
NCT06215716Lead Sponsor
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
PHASE3Recruiting
1,650 participants
Started: Dec 1, 2023 · Completed: Nov 30, 2032
NCT06161571Lead Sponsor
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
PHASE3Active, not recruiting
700 participants
Started: Nov 10, 2023 · Completed: Oct 31, 2026
NCT05039450Lead Sponsor
A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)
PHASE2Active, not recruiting
182 participants
Started: Jul 30, 2021 · Completed: May 31, 2025
NCT04767529Lead Sponsor
A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
PHASE2Completed
128 participants
Started: Feb 16, 2021 · Completed: May 2, 2024
Locations (1)
Headquarters
South SF, CA, United States
Map
Loading map...